Lyell Immunopharma Inc. (LYEL)
NASDAQ: LYELHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LYEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $441.82M
- EPS (TTM)
- -$12.61
- Dividend yield
- None
- 52-week range
- 7.20 – 45.00
- Day range
- 13.30 – 14.30
- Volume / Avg
- 171.09K / 174.76K
- Beta
- —
- Shares outstanding
- 32.02M
52-week range
LYEL stock today
On Nov 20, LYEL ended the session at $13.80, adding $0.22 (1.62%), versus the S&P 500's 3.70% decline. At this level, LYEL sits near the bottom of its 52-week range of $7.20 to $45.00: 69.3% below the high, set on Dec 22, 2025 and 91.8% above the low. LYEL is down 55.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.9%.
Lyell Immunopharma has posted a net loss over the last twelve months (EPS of -$12.61), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lyell Immunopharma
Company profileLyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Lynn Seely M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 161
- IPO year
- 2021
- Website
- lyell.com
Financial highlights
Full financialsIn fiscal 2025, Lyell Immunopharma generated $36,000 in revenue, down 41.0% from fiscal 2024, its first annual decline since 2024. Lyell Immunopharma reported a net loss of $274.4 million, compared with a loss of $343.0 million a year earlier. Operating margin was -748344.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $36.00K | $61.00K | $130.00K | $84.68M | $10.65M |
| Growth | -40.98% | -53.08% | -99.85% | +695.15% | +37.31% |
| Net income | $-274.45M | $-342.99M | $-234.63M | $-183.12M | $-250.22M |
| EPS (diluted) | $-16.06 | $-26.23 | $-18.70 | $-0.74 | $-1.84 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$37.63+172.68%
- Strong buy 2
- Buy 5
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-1.86 vs $-2.06
- Surprise
- +9.71%
LYEL news
All LYEL news- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026GlobeNewswire
- Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA SubmissionGlobeNewswire
- Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell LymphomaGlobeNewswire
- Lyell Immunopharma To Participate in November Investor EventsGlobeNewswire
Lyell Immunopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs LYEL |
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs LYEL |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs LYEL |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs LYEL |
| CTMXCytomX Therapeutics Inc. | 2.03 | -0.98% | $442.55M | vs LYEL |
| AMRNAmarin Corporation plc | 10.57 | -6.13% | $444.39M | vs LYEL |
| DMACDiaMedica Therapeutics Inc. | 8.25 | +2.87% | $445.15M | vs LYEL |
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs LYEL |
Indexes, lists and sector
Lyell Immunopharma stock FAQ
What is Lyell Immunopharma's stock price today?
LYEL last traded at $13.80 as of Nov 20, 4:00 PM EST, up 1.62% on the day. Prices are delayed at least 15 minutes.
Does Lyell Immunopharma pay a dividend?
No. Lyell Immunopharma does not currently pay a regular cash dividend.
Who is Lyell Immunopharma's CEO?
Dr. Lynn Seely M.D., Ph.D. is the chief executive officer of Lyell Immunopharma Inc., which has about 161 employees.
Has LYEL ever split its stock?
Yes. The most recent LYEL stock split was a 1-for-20 split on Jun 2, 2025.
What is the LYEL 52-week high?
The 52-week high for LYEL is $45.00 and the 52-week low is $7.20. The stock is currently 69.3% below its high.